Civitas Therapeutics, Inc., a privately-held biopharmaceutical company developing and commercializing transformative therapeutics using its proprietary ARCUSTM technology, has completed a $55 million Series C financing. Among the investors was CURE member Canaan Partnersmore

Aldea Pharmaceuticals, a company pioneering novel therapeutics to treat aldehyde metabolism disorders, today announced has closed a $24 million Series B equity financing. Investors included Canaan Partnersmore

Canaan Partners is a global venture capital firm. They were early investors in some of the world’s leading technology companies, including PrimeSense, SuccessFactors and LendingClub and healthcare stars like Cerexa, Chimerix, and Advanced BioHealing … more